chevron_leftBack
As of 13 June 2026, Theravance Biopharma, Inc. has a market cap of $857.87M USD, ranking #11642 globally and #2260 in the United States.
It ranks #1060 in the Healthcare sector, and #398 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$857.87MUSD
Enterprise Value
$573.58MUSD
Revenue (TTM)
$107.46MUSD
EBITDA (TTM)
-$1.98MUSD
Net Income (TTM)
$105.9MUSD
EBITDA Margin
-1.8%
Profit Margin
99%
PE Ratio
8.1
Forward PE
6.6
PS Ratio
8.0
PB Ratio
2.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Rick Winningham
open_in_new
Employees
90
Founded
2013
Website
theravance.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.6% | 0.6% | 11% | -12% | 19% | 71% |
News
Loading...
TBPH Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TBPH
Theravance Biopharma Inc
ISIN: KYG8807B1068
Shares Out.:
Shares Outstanding:
51.553M1
Shares Float:
48.256M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
16.66 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
89K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
64K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
42K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
32K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
17K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
14K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
37K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
34K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
32K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
21K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
13K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
13K%
80.96B GBP
|
14.6
|
chevron_leftBack